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Purpose of the study
The aim of this analysis was to examine the impact of
switching to ATR from KVX+EFV on patients percep-
tions of treatment including the following: treatment
intrusiveness, treatment satisfaction and HIV/HAART
related symptom experiences; self-reported adherence
was also assessed.
Methods
Data was collected as part of ROCKET 1, a Phase 4,
open-label, randomised, UK, multicentre, controlled
study. At baseline 159 subjects stable on KVX+EFV with
raised cholesterol were randomized 1:1 to one of two
treatment groups: Treatment Group 1 (TG1): switch to
ATR; Treatment Group 2 (TG2): continuation of pre-
vious stable regimen of KVX+EFV. At week 12, subjects
in TG2 were switched to ATR. Treatment in both
groups continued to study week 24. Subjects completed
questionnaires assessing treatment intrusiveness, satis-
faction with treatment, and symptom experiences at
baseline and at weeks 4, 12, 16, and 24. Adherence over
the preceding 30 days was measured using a visual ana-
logue scale.
Summary of results
Following the switch to ATR, 69% of subjects in TG1
indicated that they preferred their current regimen to
their previous antiretroviral regimen. At week 12,
between group comparisons showed those who switched
to ATR perceived their treatment to be more convenient
(p<0.05) and tolerable (p<0.05), reported fewer symp-
toms (p<0.0001) and were less bothered by side-effects
(p<0.005) than those who remained on KVX+EFV.
There was no difference between groups in reported
adherence: 87% of those who switched to ATR and 86%
of those who remained on KVX+EFV reported taking at
least 95% of their antiretroviral medicines over the past
30 days (p>0.05). Those who switched to ATR were
more likely than those who remained on KVX+EFV to
experience a reduction in symptoms (p<0.0001) and
treatment intrusiveness (p<0.05) between baseline and
week 12.
Conclusions
These findings indicate that switching to ATR from
KVX+EFV leads to improved perceptions of treatment
among people who have raised cholesterol. These find-
ings complement those from the primary analysis of
ROCKET 1 showing improvements in lipid profiles
among subjects who switched from KVX+EFV to ATR.
Author details
1The School of Pharmacy, University of London, London, UK.
2Gilead
Sciences, Cambridge, UK.
Published: 8 November 2010
doi:10.1186/1758-2652-13-S4-P42
Cite this article as: Cooper et al.: Switching to Atripla (EFV/FTC/TDF)
from Kivexa (ABC/3TC) plus EFV leads to improved perceptions of
treatment: results from the ROCKET 1 study. Journal of the International
AIDS Society 2010 13(Suppl 4):P42.
1The School of Pharmacy, University of London, London, UK
Full list of author information is available at the end of the article
Cooper et al. Journal of the International AIDS Society 2010, 13(Suppl 4):P42
http://www.jiasociety.org/content/13/S4/P42
© 2010 Cooper et al; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.